Titre : Annotation de séquence moléculaire

Annotation de séquence moléculaire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Annotation de séquence moléculaire : Questions médicales les plus fréquentes", "headline": "Annotation de séquence moléculaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Annotation de séquence moléculaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-10", "dateModified": "2025-05-05", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Annotation de séquence moléculaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Données de séquences moléculaires", "url": "https://questionsmedicales.fr/mesh/D008969", "about": { "@type": "MedicalCondition", "name": "Données de séquences moléculaires", "code": { "@type": "MedicalCode", "code": "D008969", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "L01.462.750.245.667" } } }, "about": { "@type": "MedicalCondition", "name": "Annotation de séquence moléculaire", "alternateName": "Molecular Sequence Annotation", "code": { "@type": "MedicalCode", "code": "D058977", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Eneida L Hatcher", "url": "https://questionsmedicales.fr/author/Eneida%20L%20Hatcher", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Linda Yankie", "url": "https://questionsmedicales.fr/author/Linda%20Yankie", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Eric P Nawrocki", "url": "https://questionsmedicales.fr/author/Eric%20P%20Nawrocki", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Jack W Roddy", "url": "https://questionsmedicales.fr/author/Jack%20W%20Roddy", "affiliation": { "@type": "Organization", "name": "Department of Computer Science, University of Montana, Missoula, MT 59812, USA." } }, { "@type": "Person", "name": "Travis J Wheeler", "url": "https://questionsmedicales.fr/author/Travis%20J%20Wheeler", "affiliation": { "@type": "Organization", "name": "Department of Computer Science, University of Montana, Missoula, MT 59812, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers.", "datePublished": "2023-07-20", "url": "https://questionsmedicales.fr/article/37511475", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms241411715" } }, { "@type": "ScholarlyArticle", "name": "A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.", "datePublished": "2023-03-07", "url": "https://questionsmedicales.fr/article/36894035", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1053/j.gastro.2023.02.044" } }, { "@type": "ScholarlyArticle", "name": "Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update.", "datePublished": "2023-02-28", "url": "https://questionsmedicales.fr/article/36855007", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12350-023-03202-w" } }, { "@type": "ScholarlyArticle", "name": "Optimal age to stop prostate cancer screening and early detection.", "datePublished": "2023-08-19", "url": "https://questionsmedicales.fr/article/37598870", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jcpo.2023.100443" } }, { "@type": "ScholarlyArticle", "name": "Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer.", "datePublished": "2022-10-03", "url": "https://questionsmedicales.fr/article/36121650", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ijc.34298" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Sciences de l'information", "item": "https://questionsmedicales.fr/mesh/D007254" }, { "@type": "ListItem", "position": 3, "name": "Sources d'information", "item": "https://questionsmedicales.fr/mesh/D000093983" }, { "@type": "ListItem", "position": 4, "name": "Services d'information", "item": "https://questionsmedicales.fr/mesh/D007255" }, { "@type": "ListItem", "position": 5, "name": "Documentation", "item": "https://questionsmedicales.fr/mesh/D004282" }, { "@type": "ListItem", "position": 6, "name": "Données de séquences moléculaires", "item": "https://questionsmedicales.fr/mesh/D008969" }, { "@type": "ListItem", "position": 7, "name": "Annotation de séquence moléculaire", "item": "https://questionsmedicales.fr/mesh/D058977" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Annotation de séquence moléculaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Annotation de séquence moléculaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Annotation de séquence moléculaire", "description": "Comment l'annotation aide-t-elle au diagnostic ?\nQuels outils sont utilisés pour l'annotation ?\nL'annotation peut-elle prédire des maladies ?\nQuels types de séquences sont annotés ?\nL'annotation est-elle standardisée ?", "url": "https://questionsmedicales.fr/mesh/D058977?mesh_terms=Early+Detection+of+Cancer&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Annotation de séquence moléculaire", "description": "Quels symptômes peuvent être liés à des mutations génétiques ?\nComment l'annotation aide-t-elle à comprendre les symptômes ?\nLes symptômes sont-ils toujours présents avec des mutations ?\nPeut-on prédire des symptômes grâce à l'annotation ?\nLes symptômes varient-ils selon les individus ?", "url": "https://questionsmedicales.fr/mesh/D058977?mesh_terms=Early+Detection+of+Cancer&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Annotation de séquence moléculaire", "description": "Comment l'annotation aide-t-elle à la prévention ?\nPeut-on prévenir des maladies grâce à l'annotation ?\nQuels tests sont utilisés pour l'annotation préventive ?\nL'éducation génétique est-elle importante pour la prévention ?\nLes programmes de dépistage sont-ils basés sur l'annotation ?", "url": "https://questionsmedicales.fr/mesh/D058977?mesh_terms=Early+Detection+of+Cancer&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Annotation de séquence moléculaire", "description": "L'annotation influence-t-elle les traitements ?\nQuels traitements sont basés sur l'annotation ?\nComment l'annotation aide-t-elle à choisir un traitement ?\nLes traitements sont-ils standardisés selon l'annotation ?\nL'annotation peut-elle aider à éviter des effets secondaires ?", "url": "https://questionsmedicales.fr/mesh/D058977?mesh_terms=Early+Detection+of+Cancer&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Annotation de séquence moléculaire", "description": "Quelles complications peuvent survenir sans annotation ?\nL'annotation peut-elle réduire les complications ?\nLes complications sont-elles prévisibles grâce à l'annotation ?\nComment l'annotation aide-t-elle à gérer les complications ?\nLes complications varient-elles selon les individus ?", "url": "https://questionsmedicales.fr/mesh/D058977?mesh_terms=Early+Detection+of+Cancer&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Annotation de séquence moléculaire", "description": "Quels facteurs de risque sont identifiés par l'annotation ?\nL'annotation peut-elle identifier des facteurs de risque environnementaux ?\nLes facteurs de risque sont-ils modifiables ?\nComment l'annotation aide-t-elle à évaluer les facteurs de risque ?\nLes facteurs de risque sont-ils les mêmes pour tous ?", "url": "https://questionsmedicales.fr/mesh/D058977?mesh_terms=Early+Detection+of+Cancer&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment l'annotation aide-t-elle au diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'identifier des gènes ou des mutations associés à des maladies." } }, { "@type": "Question", "name": "Quels outils sont utilisés pour l'annotation ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des logiciels comme BLAST et GeneMark sont couramment utilisés." } }, { "@type": "Question", "name": "L'annotation peut-elle prédire des maladies ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut aider à prédire des risques génétiques pour certaines maladies." } }, { "@type": "Question", "name": "Quels types de séquences sont annotés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les séquences d'ADN, d'ARN et de protéines sont couramment annotées." } }, { "@type": "Question", "name": "L'annotation est-elle standardisée ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il existe des standards comme GFF et BED pour uniformiser l'annotation." } }, { "@type": "Question", "name": "Quels symptômes peuvent être liés à des mutations génétiques ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés comme des malformations, des troubles métaboliques peuvent apparaître." } }, { "@type": "Question", "name": "Comment l'annotation aide-t-elle à comprendre les symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle relie les mutations à des phénotypes spécifiques, facilitant la compréhension." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents avec des mutations ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Non, certaines mutations peuvent être silencieuses et ne pas provoquer de symptômes." } }, { "@type": "Question", "name": "Peut-on prédire des symptômes grâce à l'annotation ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'annotation peut aider à anticiper des symptômes basés sur des mutations connues." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les individus ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'environnement et de la génétique." } }, { "@type": "Question", "name": "Comment l'annotation aide-t-elle à la prévention ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'identifier les individus à risque et de mettre en place des mesures préventives." } }, { "@type": "Question", "name": "Peut-on prévenir des maladies grâce à l'annotation ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en surveillant les individus porteurs de mutations à risque." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour l'annotation préventive ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques comme le séquençage de nouvelle génération sont utilisés." } }, { "@type": "Question", "name": "L'éducation génétique est-elle importante pour la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle sensibilise les individus aux risques et aux mesures préventives." } }, { "@type": "Question", "name": "Les programmes de dépistage sont-ils basés sur l'annotation ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont souvent conçus en fonction des données d'annotation disponibles." } }, { "@type": "Question", "name": "L'annotation influence-t-elle les traitements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle permet de personnaliser les traitements en fonction des mutations spécifiques." } }, { "@type": "Question", "name": "Quels traitements sont basés sur l'annotation ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements comme les thérapies géniques et les médicaments ciblés en dépendent." } }, { "@type": "Question", "name": "Comment l'annotation aide-t-elle à choisir un traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Elle identifie les cibles moléculaires pour des traitements plus efficaces." } }, { "@type": "Question", "name": "Les traitements sont-ils standardisés selon l'annotation ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Non, les traitements peuvent varier selon les spécificités de chaque cas." } }, { "@type": "Question", "name": "L'annotation peut-elle aider à éviter des effets secondaires ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en choisissant des traitements adaptés aux profils génétiques des patients." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir sans annotation ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements inappropriés et des diagnostics erronés peuvent survenir." } }, { "@type": "Question", "name": "L'annotation peut-elle réduire les complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en permettant des traitements plus ciblés et adaptés aux patients." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles grâce à l'annotation ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être anticipées en fonction des mutations identifiées." } }, { "@type": "Question", "name": "Comment l'annotation aide-t-elle à gérer les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle fournit des informations sur les risques et les options de traitement appropriées." } }, { "@type": "Question", "name": "Les complications varient-elles selon les individus ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent varier en fonction de la génétique et de l'environnement." } }, { "@type": "Question", "name": "Quels facteurs de risque sont identifiés par l'annotation ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des mutations génétiques, des antécédents familiaux et des facteurs environnementaux." } }, { "@type": "Question", "name": "L'annotation peut-elle identifier des facteurs de risque environnementaux ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut relier des mutations à des expositions environnementales spécifiques." } }, { "@type": "Question", "name": "Les facteurs de risque sont-ils modifiables ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certains, comme le mode de vie, peuvent être modifiés pour réduire les risques." } }, { "@type": "Question", "name": "Comment l'annotation aide-t-elle à évaluer les facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'analyser les données génétiques et cliniques pour une évaluation précise." } }, { "@type": "Question", "name": "Les facteurs de risque sont-ils les mêmes pour tous ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils varient selon les individus et les populations en fonction de la génétique." } } ] } ] }

Sources (10000 au total)

A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.

Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improv... The present 3-step study incorporated data from 2141 patients, including 888 with GC, 158 with chronic atrophic gastritis, 193 with intestinal metaplasia, 501 healthy donors, and 401 with other gastro... In discovery phase, one LR (GClnc1) was found to be up-regulated in both tissue and circulating EV samples with an area under the curve (AUC) of 0.9369 (95% confidence interval [CI], 0.9073-0.9664) fo... EV-derived GClnc1 serves as a circulating biomarker for the early detection of GC, thus providing opportunities for curative surgery and improved survival outcomes....

Optimal age to stop prostate cancer screening and early detection.

Prostate Cancer screening should be discontinued at older ages because competing mortality risks eventually dominate the risk of Prostate Cancer and harms exceed benefits. We explored the Prostate Can... We applied Bellman Equations to formulate the net benefits biopsy and "do nothing". Using difference between the net benefits of two alternatives, we calculated the stopping age. The cancer states wer... Our results suggested that Prostate Cancer screening stopping ages from the patient, healthcare system, and social were 70, 68, and 68 respectively. The univariate sensitivity analysis showed that the... Men should not be screened for Prostate Cancer beyond 70 years old, as this results in the net benefit of "do nothing" above the biopsy. Nevertheless, this finding needs to be further studied with mor...

Ovarian Cancer-Self Assessment: An Innovation for Early Detection and Risk Assessment of Ovarian Cancer.

The modality to detect ovarian cancer at an early stage is very limited. Early diagnosis determines the prognosis. This study aimed to develop a risk assessment tool for early detection of ovarian can... This study was carried out as a cohort study of patients diagnosed with suspected ovarian tumors undergoing cytoreduction operation at Hasan Sadikin Hospital, Bandung, from December 2019 to September ... In total, 115 patients included in this study. The differences were statistically significant in terms of the six variables (abdominal bloating, nausea/vomiting, decreased of appetite, fullness, menst... Risk assessments based on ovarian cancer self-assessment unfortunately were not comparable to postoperative histopathology as a single predictor. Ten variables in ovarian cancer artificial intelligenc...

Integration of multiomics features for blood-based early detection of colorectal cancer.

Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness o... In this research, we harnessed the Mutation Capsule Plus (MCP) technology to profile an array of genomic characteristics from cfDNA procured from a single blood draw. This profiling encompassed DNA me... This model was subsequently validated in another cohort comprising 89 CRC patients and 95 healthy controls. Remarkably, the model achieved an area under the curve (AUC) of 0.981 (95% confidence interv... Our findings underscore the clinical potential of our multiomics liquid biopsy test, indicating its prospective role as a noninvasive method for early-stage CRC detection. This multiomics approach hol...

Prospective cohort for early detection of liver cancer (Pearl): a study protocol.

Hepatocellular carcinoma (HCC) is the fastest-rising and fourth most common cause of cancer death worldwide. Liver cirrhosis is the largest underlying risk factor for HCC. Therefore, patients with cir... This is a UK-based prospective, longitudinal, diagnostic, prognostic, multicentre, non-CTIMP study. Aiming to recruit 3000 patients with liver cirrhosis without a HCC diagnosis, the Pearl cohort will ... Ethical approval has been granted by REC and the trial is registered on ClinicalTrials.gov. The results will be published in peer-reviewed journals and presented at relevant meetings.... NCT05541601....